CA2784645C - Methods and compositions related to annexin 1-binding compounds - Google Patents

Methods and compositions related to annexin 1-binding compounds Download PDF

Info

Publication number
CA2784645C
CA2784645C CA2784645A CA2784645A CA2784645C CA 2784645 C CA2784645 C CA 2784645C CA 2784645 A CA2784645 A CA 2784645A CA 2784645 A CA2784645 A CA 2784645A CA 2784645 C CA2784645 C CA 2784645C
Authority
CA
Canada
Prior art keywords
amino acid
peptide
seq
annexin
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2784645A
Other languages
English (en)
French (fr)
Other versions
CA2784645A1 (en
Inventor
Michiko Fukuda
Kazuhiro Sugihara
Naohiro Kanayama
Original Assignee
Hamamatsu University School of Medicine NUC
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamamatsu University School of Medicine NUC, Sanford Burnham Prebys Medical Discovery Institute filed Critical Hamamatsu University School of Medicine NUC
Publication of CA2784645A1 publication Critical patent/CA2784645A1/en
Application granted granted Critical
Publication of CA2784645C publication Critical patent/CA2784645C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2784645A 2009-12-23 2010-12-23 Methods and compositions related to annexin 1-binding compounds Active CA2784645C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28983309P 2009-12-23 2009-12-23
US61/289,833 2009-12-23
PCT/US2010/062072 WO2011079304A1 (en) 2009-12-23 2010-12-23 Methods and compositions related to annexin 1-binding compounds

Publications (2)

Publication Number Publication Date
CA2784645A1 CA2784645A1 (en) 2011-06-30
CA2784645C true CA2784645C (en) 2020-04-28

Family

ID=43923683

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2784645A Active CA2784645C (en) 2009-12-23 2010-12-23 Methods and compositions related to annexin 1-binding compounds

Country Status (6)

Country Link
US (3) US9610359B2 (enExample)
EP (1) EP2515944B1 (enExample)
JP (2) JP6184101B2 (enExample)
CA (1) CA2784645C (enExample)
SG (2) SG10201704812TA (enExample)
WO (1) WO2011079304A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10030036B2 (en) * 2009-05-15 2018-07-24 Lahjavida, Llc Method and dyes for detecting and destroying cancer cells
CN102898527B (zh) * 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
PL3468621T3 (pl) * 2016-06-10 2023-01-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Domena rdzeniowa aneksyn i jej zastosowania w dostarczaniu antygenu i szczepieniu
PH12019500306B1 (en) * 2016-08-16 2024-02-21 Aist Malignant tumor target peptide
CN110177566A (zh) * 2016-09-30 2019-08-27 伊夫7治疗公司 用于制备靶向肿瘤-脉管系统的抗肿瘤剂的方法
JP6856227B2 (ja) 2017-02-09 2021-04-07 株式会社Ｃｉｃｓ 計測装置
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤
WO2019138944A1 (ja) * 2018-01-09 2019-07-18 学校法人藤田学園 細胞殺傷剤
WO2019222618A1 (en) * 2018-05-17 2019-11-21 The Trustees Of Columbia University In The City Of New York Methods for treating, preventing and detecting the prognosis of colorectal cancer
JP7440914B2 (ja) * 2018-06-20 2024-02-29 国立大学法人弘前大学 ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤
JP7224628B2 (ja) * 2019-02-01 2023-02-20 国立研究開発法人産業技術総合研究所 抗ｍｃ１６抗体
US12109276B2 (en) 2019-03-15 2024-10-08 Lahjavida, Llc Near-infrared dyes and conjugates for targeting tumors
JP2022525791A (ja) * 2019-03-26 2022-05-19 株式会社島津製作所 光免疫療法およびそれに用いる薬剤
CN111120645B (zh) * 2019-12-30 2021-10-08 潍柴动力股份有限公司 一种挡位控制方法、装置及电子设备
US12370266B2 (en) 2022-09-13 2025-07-29 Core Quantum, Inc. Polymer composite nanomaterial encapsulation system
CN116199748B (zh) * 2023-01-16 2025-08-05 中国地质大学（武汉） 多肽荧光探针及其在检测活细胞内聚集蛋白中的应用
CN116606351B (zh) * 2023-04-17 2025-04-18 合肥师范学院 一种基于理性分子设计构建的抗菌肽hsp-m4及制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1016978B (de) 1955-05-16 1957-10-03 Iashellia Res Ltd Mittel zur Bekaempfung des Pflanzenwachstums
CH588887A5 (enExample) 1974-07-19 1977-06-15 Battelle Memorial Institute
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4418052A (en) 1980-08-12 1983-11-29 Wong Dennis W Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4761288A (en) 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US5628936A (en) 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5474848A (en) 1987-03-13 1995-12-12 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4853228A (en) 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
US5011686A (en) 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
US5013497A (en) 1988-03-03 1991-05-07 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5024829A (en) 1988-11-21 1991-06-18 Centocor, Inc. Method of imaging coronary thrombi
US5643873A (en) 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5897945A (en) 1996-02-26 1999-04-27 President And Fellows Of Harvard College Metal oxide nanorods
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
NZ508669A (en) 1998-06-11 2003-06-30 Dimensional Pharm Inc Pyrazinone protease inhibitors
US6451969B1 (en) * 1999-01-15 2002-09-17 The Burnham Institute Methods for inhibiting tumor metastasis, and peptides useful therfor
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US20040037775A1 (en) * 2000-08-01 2004-02-26 Siahaan Teruna J. Leukocyte internalized peptide-drug conjugates
ATE346074T1 (de) 2000-11-30 2006-12-15 Penn State Res Found Dna methyl transferase inhibitoren
NZ538869A (en) * 2002-09-27 2006-09-29 Nihon Mediphysics Co Ltd Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient

Also Published As

Publication number Publication date
CA2784645A1 (en) 2011-06-30
SG10201704812TA (en) 2017-07-28
SG181899A1 (en) 2012-07-30
US20120251453A1 (en) 2012-10-04
JP6331030B2 (ja) 2018-05-30
WO2011079304A1 (en) 2011-06-30
US20170326245A1 (en) 2017-11-16
JP6184101B2 (ja) 2017-08-23
US20210260202A1 (en) 2021-08-26
JP2015110668A (ja) 2015-06-18
JP2013515745A (ja) 2013-05-09
EP2515944A1 (en) 2012-10-31
US9610359B2 (en) 2017-04-04
EP2515944B1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
US20210260202A1 (en) Methods and Compositions Related to Annexin 1-Binding Compounds
US20170246236A1 (en) Methods and compositions for enhanced delivery of compounds
US12195558B2 (en) Targeted delivery system and methods of use therefor
EP2445536B1 (en) Methods and compositions using peptides and proteins with c-terminal elements
EP2510943B1 (en) Methods and compositions related to targeting tumors and wounds
US20120034164A1 (en) Truncated car peptides and methods and compositions using truncated car peptides
US10179801B2 (en) Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
JP2014159434A (ja) ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用
US8912136B2 (en) Methods and compositions related to clot-binding compounds
WO2012118778A1 (en) Truncated car peptides and methods and compositions using truncated car peptides
HK1176299B (en) Methods and compositions related to annexin 1-binding compounds
HK1176299A (en) Methods and compositions related to annexin 1-binding compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151208